Skip to main content

Table 3 General information and therapeutic outcomes on 5 patients with coexistent genetic alterations including EGFR, ROS1, and EML4-ALK in MPA and LA patients

From: A comprehensive study on the oncogenic mutation and molecular pathology in Chinese lung adenocarcinoma patients

Patients 1 2 3 4 5
Gender Female Male Female Male Female
Age (years) 52 31 45 71 75
Smoking history Never Never Never Ever Never
Lymphovascular invasion Absent Present Absent Absent Absent
Tumor differentiation Moderate Moderate Moderate Moderate Moderate
Stage T1bN0M0 T1cN1M0 T1cN0M0 T1bN0M0 T1cN0M0
Pathological type MPA MPA MPA MPA LA
Mutation status ROS1+; EML4-ALK+ ROS1+; EML4-ALK+ EGFR L858R+; ROS1+ EGFR L858R+; ROS1+ EGFR 19-del+; ROS1+
Therapeutic intervention Surgery; chemotherapy; crizotinib Surgery; chemotherapy; crizotinib Surgery; chemotherapy; EGFR inhibitors Surgery; chemotherapy; EGFR inhibitors Surgery; chemotherapy; EGFR inhibitors
Outcomes Partial response Partial response Partial response Recurrence Partial response
  1. MPA micropapillary lung adenocarcinoma, LA lung adenocarcinoma without micropapillary component, EGFR+ EGFR mutation, ROS1+ ROS1 fusion, EML4-ALK+ EML4-ALK fusion